Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.67 USD
-0.03 (-4.41%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.68 +0.01 (1.19%) 7:46 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APTO 0.67 -0.03(-4.41%)
Will APTO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APTO
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Aptose Biosciences (APTO) a New Buy Stock
APTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Other News for APTO
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Biosciences Shareholders Approve Key Proposals
Tuspetinib: A Promising Candidate for Enhancing r/r AML Treatment Outcomes
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Biosciences Issues Non-Filed Information Disclosure